



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 97-022-F3)

PATENT

In the Application of:)
R. Terry Dunlay, et al.)
Serial No.: 09/718,770)
Filed: November 22, 2000)
Title: A System for Cell based Screening) Art Unit: 1631
Examiner: Smith
Conf. No.: 5398

INFORMATION DISCLOSURE STATEMENT

**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the Foreign and Journal references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

02/06/2006 SHASSEN1 00000045 132490 09718770

02 FC:1806 180.00 DA

This Information Disclosure Statement is being filed:

within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)

after three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):

the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below)

OR

the fee of \$180.00 set forth in 37 C.F.R. § 1.17(p) (see "Fees" below).

after a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see "Fees" and "Method of Payment of Fees" below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

CERTIFICATION

- The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES


- No fee is owed by the applicant(s).
 The IDS Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
 One (1) Month Extension of Time.

METHOD OF PAYMENT OF FEES

- The Commissioner is authorized to charge our Deposit Account No.: 13-2490 in the amount of \$300.00 for the Large Entity IDS fee (\$180.00) and One (1) Month Extension of Time (\$120.00).

CERTIFICATE OF MAILING VIA EXPRESS MAIL DELIVERY under 37 C.F.R. § 1.10. I hereby certify that the attached paper of fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box 1450, Alexandria, VA, 22313-1450, on this 1st day of February, 2006. Express Mail No. EV757105170US.

Respectfully submitted,



David S. Harper
Registration No. 42,636

Article References:

1. "Cray And BioNumerik Pharmaceuticals: Engineering More Rapid Cures For Today's Diseases", www.cray.com/features/bionumerik.html, pages 1-3. Printed on April 9, 2000.
2. "CS 267 Assignment One-Drug Design", garnet, Berkley.edu/~abeand/cs267/assignment1.html, pages 1-2. Printed on April 9, 2000.
3. "Knowledge Management And Knowledge Automation Systems", Gallagher Financial System, Inc., pages 1-6, Printed on April 9, 2000.
4. Project Explorer: Enabling Knowledge Led R & D Projects", www.synomics.com/m/products/projectexplorer.htm, pages 1-3, Printed on April 9, 2000.
5. BIOREASON – Automated Reasoning System For Drug Discovery, www.bioreason.com, Printed on April 9, 2000.
6. Commercial Bioinformatics Software, www.uk.embl.org/data/www/CCP11/commercial_software.txt.html, pages 1-12, Printed on August 24, 2000.

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001

7. Nathan Goodman, "The Fundamental Principles For Constructing A Successful Biological Laboratory Informatics System", Scientific Computing and Automation 8: 1-11, 1996
8. Inpharmatica – World Class Bioinformatics, www.inpharmatica.co.uk, various articles, Printed on April 9, 2000


In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Date:

2/1/06

By:

Respectfully Submitted,



David S. Harper
Registration No. 42,636


FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

97-022-F3

Serial No.

09/718,770



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

R. Terry Dunlay et al.

Filing Date: November 22, 2000 **Group:** 1631**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	1. "Cray And BioNumerik Pharmaceuticals: Engineering More Rapid Cures For Today's Diseases", www.cray.com/features/bionumerik.html , pages 1-3. Printed on April 9, 2000
	2. "CS 267 Assignment One - Drug Design", garnet.Berkley.edu/~abeand/cs267/assignment1.html , pages 1-2. Printed on April 9, 2000

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


Serial No.

97-022-F3

09/718,770

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

R. Terry Dunlay et al.

Filing Date:

November 22,
2000

Group:

1631

	3. "Knowledge Management And Knowledge Automation Systems", Gallagher Financial System, Inc., pages 1-6, Printed on April 9, 2000
	4. Project Explorer: Enabling Knowledge Led R & D Projects", www.synomics.com/m/products/projectexplorer.htm , pages 1-3, Printed on April 9, 2000.
	5. BIOREASON – Automated Reasoning System For Drug Discovery, www.bioreason.com , Printed on April 9, 2000
	6. Commercial Bioinformatics Software, www.uk.embnet.org/data/www/CCP11/commercial_software.txt.html , pages 1-12, Printed on August 24, 2000
	7. Nathan Goodman, "The Fundamental Principles For Constructing A Successful Biological Laboratory Informatics System", Scientific Computing and Automation 8: 1-11, 1996
	8. Inpharmatica – World Class Bioinformatics, www.inpharmatica.co.uk , various articles, Printed on April 9, 2000

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001